5.12. Example 11

Aerosol Dosage Form

A concentrate is prepared by combining Compound A, and a 12.6 kg portion of the trichloromonofluoromethane in a sealed stainless steel vessel equipped with a high shear mixer. Mixing is carried out for about 20 minutes. The bulk suspension is then prepared in the sealed vessel by combining the concentrate with the balance of the propellants in a bulk product tank that is temperature controlled to 21° to 27° C. and pressure controlled to 2.8 to 4.0 BAR. 17 ml aerosol containers which have a metered valve which is designed to provide 100 inhalations of the composition of the invention. Each container is provided with the following:

Compound A	0.0120 g
trichloromonofluoromethane	1.6939 g
dichlorodifluoromethane	3.7175 g
dichlorotetrafluoroethane	1.5766 g
total	7.0000 g

While the invention has been described with respect to the particular embodiments, it will be apparent to those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the invention as defined in the claims. Such modifications are also intended to fall within the scope of the appended claims.

What is claimed is:

1. A method of treating an arthritic condition, which comprises administering to a patient having an arthritic condition a therapeutically effective amount of a compound which is stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione.

2. The method of claim **1**, wherein the arthritic condition is rheumatoid spondylitis.

3. The method of claim **1**, wherein the compound is administered orally.

4. The method of claim **3**, wherein about 5 mg to about 500 mg of the compound is administered per day.

5. The method of claim **3**, wherein about 10 mg to about 200 mg of the compound is administered per day.

6. The method of claim **3**, wherein about 10 mg to about 100 mg of the compound is administered per day.

7. The method of claim **3**, wherein the compound is administered twice daily in equally divided doses.

8. The method of claim **3**, wherein the stereomerically pure compound comprises greater than about 90% by weight of (+) isomer based on the total weight percent of the compound.

9. The method of claim **3**, wherein the stereomerically pure compound comprises greater than about 95% by weight of (+) isomer based on the total weight percent of the compound.

10. The method of claim **3**, wherein the stereomerically pure compound comprises greater than about 97% by weight of (+) isomer based on the total weight percent of the compound.

11. The method of claim **3**, wherein the compound is administered in capsule form.

12. The method of claim **1**, wherein the capsule contains about 10 mg of the compound.

13. The method of claim **11**, wherein the capsule contains about 20 mg of the compound.

14. The method of claim **11**, wherein the capsule contains about 25 mg of the compound.

15. The method of claim **11**, wherein the capsule contains about 50 mg of the compound.

16. The method of claim **1**, wherein the compound is administered in tablet form.

17. The method of claim **16**, wherein the tablet contains about 10 mg of the compound.

18. The method of claim **16**, wherein the tablet contains about 20 mg of the compound.

19. The method of claim **16**, wherein the tablet contains about 25 mg of the compound.

20. The method of claim **16**, wherein the tablet contains about 50 mg of the compound.

21. A method of treating an arthritic condition, which comprises orally administering to a patient having an arthritic condition about 10 mg to about 100 mg of a compound which is stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione comprising greater than about 97% by weight of (+) isomer wherein the compound is administered in the form of a tablet or capsule twice daily in equally divided doses.

22. The method of claim **21**, wherein the arthritic condition is rheumatoid spondylitis.

* * * * *